Spago’s CEO: “We want to expand cancer treatment with effective radiopharmaceuticals”

2024 has marked a defining chapter for Spago Nanomedical, solidifying its position in radionuclide therapy.

By focusing its energy on the lead Tumorad programme, the company achieved important milestones during the year. BioStock has spoken with CEO Mats Hansen to have him reflect on the past year and look ahead to 2025.